Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results vaccine efficacy after dose 1 (and before dose 2) E

COVID-19 prophylaxis (excluding children) meta-analysis

BNT162b2 phase 3 (C4591001, Polack)
 
NCT04368728
RCTComirnaty (tozinameran - Pfizer/BIONTECH)placeboCOVID-19 prophylaxis (excluding children)some concern
21720/21728 conclusif -47%
Nguyen OBSComirnaty (tozinameran - Pfizer/BIONTECH)Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)COVID-19 prophylaxis (excluding children)NA
-/- inconclusive
Amit OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
7214/1895 suggested -76%
Dagan OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
596618/596618 suggested
SIREN (HW england)
 
ISRCTN11041050
OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)serious
-/- suggested -63%
Scotland cohort unpublished OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- suggested -76%
Shemer OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- inconclusive
Husby (pfizer) OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- inconclusive
Patone OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- safety concern
Shasha OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- safety concern
Angel OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
5517/757 suggested
Barda OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)critical
-/- safety concern
Bernal (PHE, 19th February 2021) OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- suggested
Bjork OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- suggested
Chodcik OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)serious
503875/351897 inconclusive -46%
EPI-PHARE OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)critical
-/- inconclusive
Goldberg OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- suggested
Haas OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- suggested
Heymann OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- suggested
Klein OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)critical
-/- suggested
Nanduri OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)serious
-/- suggested
Pawlowski OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- inconclusive
Shibli OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- safety concern
Tartof
 
NCT04848584
OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (children), COVID-19 prophylaxis (excluding children)NA
-/- suggested
Weekes OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- suggested
Abu-Raddad OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- no results
England (Andrews) OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
581/130867 suggested
South Africa (Discovery Health, Collie) OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)NA
-/- suggested
Tenforde OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)serious
1194/1895 suggested
Wan OBSComirnaty (tozinameran - Pfizer/BIONTECH)controlCOVID-19 prophylaxis (excluding children)critical
-/- safety concern
Palich DESCComirnaty (tozinameran - Pfizer/BIONTECH)uncontrolled studyCOVID-19 prophylaxis (excluding children)NA
-/- no results
Rozen-Zvi DESCComirnaty (tozinameran - Pfizer/BIONTECH)uncontrolled studyCOVID-19 prophylaxis (excluding children)NA
-/- no results
Yanay DESCComirnaty (tozinameran - Pfizer/BIONTECH)uncontrolled studyCOVID-19 prophylaxis (excluding children)NA
-/- no results
Zadok DESCComirnaty (tozinameran - Pfizer/BIONTECH)uncontrolled studyCOVID-19 prophylaxis (excluding children)NA
-/- no results

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).